Virtual Library
Start Your Search
M. Ilouze
Author of
-
+
P3.03 - Chemotherapy/Targeted Therapy (ID 719)
- Event: WCLC 2017
- Type: Poster Session with Presenters Present
- Track: Chemotherapy/Targeted Therapy
- Presentations: 1
- Moderators:
- Coordinates: 10/18/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)
-
+
P3.03-022 - Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement but Better Survival (ID 9887)
09:30 - 09:30 | Author(s): M. Ilouze
- Abstract
Background:
Young patients with Non-small cell lung cancer (NSCLC) represent a distinct subset of patients. There are few reports describing younger patient’s characteristics and survival. Therefore, we conducted a retrospective study, in which we gathered clinical features of NSCLC patients under the age of 50 and matched patients who were older than 60 years at diagnosis.
Method:
Retrospective data of NSCLC patients was collected in a single tertiary hospital between January 2010 and December 2015. Patients were divided into 2 age groups according to the age at diagnosis: younger than 50 years (N=62) and older than 60 years (N=124). Their clinico-pathological characteristics, disease course and survival rate were analyzed.
Result:
The median age was 44 and 68 years of the younger and older cohort respectively. There were more never smokers (36% vs. 24%, p=0.08) and more brain metastasis (40% vs. 25%, p =0.04) in the younger group. Interestingly enough, upper lobes were more involved in the older vs. the younger cohort (p<0.001). A similar percentage of patients underwent NGS testing in both groups, but driver mutations were more common in the younger cohort: Epidermal Growth Factor Receptor (EGFR) mutations (32% vs. 25%, NS), Anaplastic Lymphoma Kinase (ALK) rearrangement (22% vs. 3%, p =0.002). Accordingly, the clinical impact of molecular testing on treatment decision was greater in the young vs. the older group (61% vs. 31%, p=0.002). Median survival was longer in the younger cohort, although not significantly different (34 vs. 21 months, p =0.1).
Conclusion:
Young patients with NSCLC have more driver mutations, more brain metastases and a trend of better survival. Therefore, this group of patients should undergo intensive mutation investigation and brain MRI on initial assessment.
